COVID-19: long-term respiratory consequences

Toufen, Carlos; Pêgo-Fernandes, Paulo Manuel

doi:10.1590/1516-3180.2021.139526052021

Cited by 3 publications

(1 citation statement)

References 9 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COVID-19 has an average incubation period of 5– 6 days but can extend up to 14 days. As of the end of 2022, a total of 6.6 million deaths out of 50 million COVID-19 cases have been reported worldwide [ 2 ]. In Indonesia, the overall incidence of COVID-19 was 2,050 per 100,000 populations, with a mortality rate of 55 per 100,000 populations [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Factors associated with small airway obstruction in COVID-19 survivors: A cross-sectional study among health-care providers

Aritonang,

Pandia,

Pradana

et al. 2023

Narra J

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has been identified for more than two years, yet studies assessing post-infection lung function are limited. Reports on lung function in COVID-19 patients indicate that patients have restrictive defects and small airway dysfunction that can persist and are not necessarily related to the severity of the disease. The aim of this study was to assess the incidence of small airway obstruction and its incidence-associated factors among COVID-19 survivors to better describe the long-term effects of COVID-19. A cross-sectional study was conducted among COVID-19 survivors who less than 50 years at Medan Adventist Hospital between 2020–2022. The data were collected through interview, direct assessment and respiratory examination. A total of 89 COVID-19 survivors were recruited of which the majority of them were female with a mean age of 32.6-year-old with the largest group was 19–30 years. The comorbidities found among the survivors were heart and thyroid disorders, with the most common symptom of post-COVID-19 was fatigue. Most of them had mild COVID-19. The mean forced mid-expiratory flow (FEF25–75%) was 96.3±20.22, with an incidence rate of small airway obstruction was 19.1%. Univariate and multivariate analyses indicated no significant association between age, gender, comorbidities, history of oxygenation during COVID-19 treatment, COVID-19 severity and the type of post COVID-19 syndrome symptoms with the incidence of small airway obstruction. In conclusion, among COVID-19 survivors who were less than 50 years old, those studied variables seems have less association with the incidence of small airway obstruction. Nevertheless, a further study with a bigger sample size is important to be conducted.

show abstract

Section: Introductionmentioning

confidence: 99%

Factors associated with small airway obstruction in COVID-19 survivors: A cross-sectional study among health-care providers

Aritonang,

Pandia,

Pradana

et al. 2023

Narra J

View full text Add to dashboard Cite

show abstract

Alamandine: A promising treatment for fibrosis

Fernandes

Neto

Carvalho³

et al. 2022

Peptides

View full text Add to dashboard Cite

Network pharmacology and molecular docking reveal the mechanisms of action of Panax notoginseng against post-COVID-19 thromboembolism

Yuan,

Obaidi,

Zhang

et al. 2024

Rev. Clin. Pharmacol. Pharmacokinet., Int. Ed.

View full text Add to dashboard Cite

Panax notoginseng (PNGS) is a potent folk therapy for blood-related diseases. However, further research is required to fully elucidate the mechanisms of its pharmacological activities and to explore its therapeutic potential for treating thromboembolism (TE) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed at analysing the molecular mechanisms of PNGS and at clarifying their potential role in treating TE induced by COVID-19, by employing network pharmacology and molecular docking. To this end, a network pharmacological ap¬proach was combined with expression profiling by high-throughput sequencing of GSE156701 so as to elucidate the compound constituents of PNGS for treating TE caused by SARS-CoV-2 at a systemic level. Protein-protein interac¬tion network, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes analyses were employed in order to decipher the associated drug-target interactions. The integration of these results suggested that five targets, including the angiotensin-converting enzyme (ACE), the coagulation factor III (F3), interleukin-1 beta (IL-1β), the mitogen-activated protein kinase 1 (MAPK1), and the plasminogen activator inhibitor-1 (SERPINE1), represent major genes involved in thromboembolism. The data suggest that PNGS exerts collective therapeutic effects against TE caused by SARS-CoV-2, and provides a theoretical basis for further laboratory study of the active drug-like ingredients and the potential mechanisms of PNGS in TE treatment.

show abstract

COVID-19: long-term respiratory consequences

Cited by 3 publications

References 9 publications

Factors associated with small airway obstruction in COVID-19 survivors: A cross-sectional study among health-care providers

Factors associated with small airway obstruction in COVID-19 survivors: A cross-sectional study among health-care providers

Alamandine: A promising treatment for fibrosis

Network pharmacology and molecular docking reveal the mechanisms of action of Panax notoginseng against post-COVID-19 thromboembolism

Contact Info

Product

Resources

About